Top Questions in Alcohol-Associated Liver Disease: A Community Conversation on Glucagon-like Peptide-1 Receptor Agonists, Sex, and Integrated Care

Nov 07 2026
Convention Center: Summit 3, The Park @TLM, Hall D
3:45 PM - 4:45 PM

World Class Speakers

Esperance Schaefer

Presenter
Esperance Schaefer, MD, MPH

Divya Ayyala

Presenter
Divya Ayyala, MD, , MAS

Sonali Paul

Presenter
Sonali Paul, MD, MS

Rebecca Roediger

Presenter
Rebecca Roediger, MD

Brittany Bromfield

Moderator
Brittany Bromfield, MBBS

Jay Luther

Moderator
Jay Luther, MD

Description

Alcohol-associated liver disease (ALD) is evolving faster than our clinical paradigms. Women are developing severe ALD at unprecedented rates despite lower alcohol consumption levels. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer tantalizing dual benefits for cravings and steatosis. Traditional screening tools may miss high-functioning patients with metabolic risk.

This rapid-fire community conversation tackles 4 critical questions hepatologists face daily, moving from, "Is there a safe drinking limit?" to, "Why do systemic barriers prevent integrated alcohol use disorder care?" Four expert discussants present emerging data and clinical realities in focused segments, followed by an open panel discussion and audience questions and answers for crosscutting synthesis.

Presentations

3:45 PM - 3:55 PM
Convention Center - Summit 3, The Park @TLM, Hall D

Is There a "Safe" Alcohol Limit? Navigating the Clinical Reality of Harm Reduction

Esperance Schaefer, MD, MPH | Presenter
3:55 PM - 4:05 PM
Convention Center - Summit 3, The Park @TLM, Hall D

Glucagon-like Peptide-1 Receptor Agonists for Alcohol-Associated Liver Disease—Ready for Primetime?

Divya Ayyala, MD, , MAS | Presenter
4:05 PM - 4:15 PM
Convention Center - Summit 3, The Park @TLM, Hall D

Beyond Biology—Why Are Women Experiencing Disproportionate Alcohol-Associated Liver Disease Progression Despite Lower Consumption?

Sonali Paul, MD, MS | Presenter
4:15 PM - 4:25 PM
Convention Center - Summit 3, The Park @TLM, Hall D

What Are the Barriers for Integrated Alcohol Use Disorder/Alcohol-Associated Liver Disease Care in Hepatology?

Rebecca Roediger, MD | Presenter
4:25 PM - 4:45 PM
Convention Center - Summit 3, The Park @TLM, Hall D

Panel Discussion and Audience Questions and Answers

Brittany Bromfield, MBBS | Moderator

Objectives

  • Evaluate the evidence base and practical considerations for prescribing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with concurrent alcohol use disorder and hepatic steatosis.
  • Apply evidence-based alcohol consumption thresholds when counseling patients with early-stage steatotic liver disease, distinguishing when harm reduction is appropriate versus abstinence.
  • Identify sex-specific biologic vulnerabilities and metabolic risk factors driving disproportionate alcohol-associated liver disease progression in women and metabolic-risk populations.

Copyright © 2026 American Association for the Study of Liver Diseases

AASLD 2026